source
- Claris collects $118M to take eye drop into pivotal testing next yearClaris Bio has a fresh CEO, new board chair and $118 million for two pivotal trials to see if its eye drop can succeed in a blinding disease with no pharmaceutical treatment options. It's a ...
- Updated: GSK reveals three-year blueprint to cut costs and propel R&DJust a little over six months into his tenure as CEO at GSK, Luke Miels is making his mark. The drugmaker on Tuesday outlined plans for a three-year cost-cutting initiative, the launch of at least ...